Harrow Inc (HROW) Stock Price, Quote & News

Company Profile

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 615 733 4730

Website: www.harrow.com

Address:

1A Burton Hills Boulevard, Suite 200, Nashville, United States

DoubleUpwithChuck Jul. 4 at 7:25 PM

$ELTP meh he should have never mentioned a sale of the company until he accepted an offer. Not the biggest mistake in the world. But if we compare results, unprofitable $1.6BN market cap $HROW has guided for and is dreaming of $40M in profit and an associated $3BN market cap valuation. We already have $40M in profit. And if we look at $5.5BN market cap $AMRX they have about $70M in profit but it takes them $3BN in revenue to get there (low margins). $ANIP Twice our income. 6X our market cap. The Purdue money is coming. So is the Anticoagulant money. No point in selling now. Especially when you see those fails to deliver from September. I’d avoid shorting here.

0 · Reply

DoubleUpwithChuck Jul. 3 at 8:30 PM

$ELTP what does $HROW have that we don’t have?

0 · Reply

Finnish_boy Jul. 2 at 6:52 PM

$HROW My final post until iheezo launch news (i promise) INVESTOR DAY 2026 BIG CATALYST: "but management foresees years from now evolving to taking on more risk (in fact, Harrow's next 5-year plan currently being drafted contemplates a bit more risk)." "We approach this upcoming 2027-2031 plan with the exact same founder's mentality, but now – with vastly superior resources, a larger commercial infrastructure, and the broadest and most clinically valuable portfolio in our history."

1 · Reply

Stacks_Edwards Jul. 2 at 2:52 PM

$HROW

2 · Reply

Finnish_boy Jul. 2 at 2:48 PM

$HROW No excitment here. Have to keep break from posting.

1 · Reply

Finnish_boy Jul. 2 at 2:41 PM

$HROW

0 · Reply

Finnish_boy Jul. 2 at 2:06 PM

$HROW Short squeeze is possible. If Lupton share all the Cantor nuggets and MV. Cunha starts posting stuff again. IHEEZO launch soon. Lets go!

0 · Reply

Finnish_boy Jul. 2 at 1:37 PM

$HROW

0 · Reply

Finnish_boy Jul. 2 at 1:00 PM

$HROW Flashy we are back.

0 · Reply

Finnish_boy Jul. 2 at 12:53 PM

$HROW Shorties, indexes are up, HROW to $50 and after that $100. lets cook! WE WILL MAKE MONEY!

0 · Reply

Harrow announces commercial launch of Byooviz in the U.S.

2026-07-01T11:11:21.000Z - 3 days ago

Harrow announces commercial launch of BYOOVIZ in U.S.

Jul 1, 2026, 7:00 AM EDT - 3 days ago

Harrow Announces Commercial Launch of BYOOVIZ® in the United States

Jul 1, 2026, 7:00 AM EDT - 3 days ago

Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow

Jun 10, 2026, 7:00 AM EDT - 24 days ago

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

Jun 3, 2026, 9:40 AM EDT - 4 weeks ago

Harrow Transcript: 46th Annual William Blair Growth Stock Conference

Jun 3, 2026, 9:40 AM EDT - 4 weeks ago

Harrow Slides: 46th Annual William Blair Growth Stock Conference

May 27, 2026, 7:00 AM EDT - 5 weeks ago

Harrow to Present at William Blair's 46th Annual Growth Stock Conference

2026-05-15T14:31:15.000Z - 7 weeks ago

Harrow CEO buys $302K, CFO buys $104.7K in common stock

2026-05-14T13:54:22.000Z - 7 weeks ago